FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Delays Review Action on Alzheimers Drug

[ Price : $8.95]

FDA delays by three months its decision on Eisai and Biogen's subcutaneous starting-dose formulation of Alzheimers drug Leqembi (l...

Legal Analysis Highlights Impact of FDA AI Clinical Trial Pilot

[ Price : $8.95]

A legal analysis published by Crowell & Moring says a proposed FDA pilot program on artificial intelligence in early-stage clinica...

Trump Denies Makary is on the Outs

[ Price : $8.95]

President Trump tells reporters he knows nothing about reports suggesting FDA commissioner Marty Makary will be asked to resign so...

FDA Input Sought on Drug Repurposing

[ Price : $8.95]

FDA seeks public input on ways to expand drug repurposing efforts, aiming to accelerate treatment options for patients with unmet ...

Guide on Developing Clostridioides Difficile Infection

[ Price : $8.95]

FDA issues updated guidance for companies developing therapies to treat, prevent or reduce recurrence of Clostridioides difficile ...

Guide on Submitting Continuous Glucose Monitoring Data

[ Price : $8.95]

FDA posts new technical guidance document outlining how sponsors should submit continuous glucose monitoring data collected during...

Boston Scientific Device Correction on Certain Pacemakers

[ Price : $8.95]

Boston Scientific begins a Class 1 recall (device correction) involving certain pacemakers and cardiac resynchronization therapy p...

White House Reportedly Moves to Oust Commissioner Makary

[ Price : $8.95]

Several media outlets report that President Trump has signed off on a plan to remove FDA commissioner Marty Makary from his post.

Partner Therapeutics Wins Approval for Bile Duct Cancer Therapy

[ Price : $8.95]

FDA approves a Partner Therapeutics BLA for Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable or metastatic cho...

Atara says FDA outlined potential path for Cell Therapy Resubmission

[ Price : $8.95]

Atara Biotherapeutics says it and partner Pierre Fabre Pharmaceuticals have received feedback from FDA outlining a potential path ...